Oslo, Norway, 12 August 2020 – Targovax ASA (OSE: TRVX) will announce its second quarter and first half 2020 results on Thursday 20 August 2020. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00am CET.
The results report and the presentation will be available at www.circio.com in the Investors section from 7:00am CET.
Presentation
As a consequence of the Corona situation, there will only be a virtual presentation of the results with a live webcast 20 August at 10.00am CET. You can join the webcast here. It will be possible to ask questions during the presentation.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.